FDA Approves Vera's Trutakna: First Dual-Target IgAN Therapy Sets Up Market Showdown with Novartis and Otsuka

The FDA has granted accelerated approval to Vera Therapeutics' Trutakna (atacicept-vymj) for reducing proteinuria in adults. The approval positions Trutakna against an increasingly crowded field that includes Novartis' Fabhalta and Otsuka's Voyxact, with Vera's drug entering a market projected to reach $50 billion in 2026.

Vera Therapeutics has crossed the regulatory finish line with Trutakna, securing FDA accelerated approval for adults with primary IgA nephropathy at risk for disease progression. The approval was expected and is based on a prespecified interim analysis of the ongoing Phase 3 ORIGIN 3 trial. Patients treated with Trutakna achieved a 46% reduction from baseline in proteinuria, with a statistically significant 42% reduction compared to placebo at 36 weeks.

Trutakna is a recombinant fusion protein designed to inhibit B-cell activation by binding to BAFF and APRIL, two cytokines involved in the survival and maturation of certain immune cells. It is the first FDA-approved therapy to target both pathways simultaneously, a mechanism Vera believes could offer broader coverage of the disease's pathophysiology. The approved dose is a 150 mg subcutaneous injection administered once weekly via an auto injector.

The approval lands in a dramatically different landscape than when Vera in-licensed atacicept from Merck KGaA six years ago. At that time, patients with IgAN had no FDA-approved treatment options. Today, Trutakna becomes the sixth drug approved for the rare kidney disease, facing competition from Novartis' Fabhalta (iptacopan), Otsuka's Voyxact (sibeprenlimab), and other established therapies including Filspari (sparsentan) from Travere Therapeutics and Tarpeyo (budesonide) from Calliditas Therapeutics. The IgAN market is estimated to reach $50.38 billion in 2026 and $107.23 billion by 2036.

Analysts noted that Trutakna's label may provide a competitive advantage over Voyxact. Otsuka's APRIL inhibitor was approved for patients at high risk of disease progression, while Vera's label is for patients at risk of disease progression, granting access to a broader patient population." The product label is in line with our bullish expectations," analysts from Guggenheim wrote. "We are encouraged that the product received a broad approval with no limitations on use based on proteinuria levels and that there is no mention of neutralizing antibodies in the label."

The accelerated approval is based on the reduction of proteinuria, and it has not yet been established whether Trutakna slows kidney function decline over the long-term. Continued approval is contingent upon verification of clinical benefit through the ongoing ORIGIN 3 trial, which is evaluating change in estimated glomerular filtration rate. Vera has aligned with the FDA on an updated analysis plan, with eGFR results now expected in the third quarter of 2026, earlier than previously anticipated. A supplemental BLA is targeted for Q4 2026, with potential full approval in 2027.

Vera's shares rose more than 8% on the news to $43.47. The company is launching Trutakna alongside a patient support program called TRU SUPPORT, offering insurance coverage assistance, financial support for eligible patients, and educational resources. Commercially insured patients may pay as little as $0 out of pocket through the company's copay assistance program.

Here is the question this approval raises. A dual-target therapy that reduces proteinuria by 46% is now entering a market with five existing competitors. But its long-term kidney function benefit remains unproven. When the confirmatory eGFR data arrives in Q3, will Trutakna's dual mechanism prove its worth against single-target rivals or will Vera's accelerated approval become a cautionary tale about the gap between surrogate endpoints and clinical reality?

As the FDA approves Trutakna and sets up a market battle with Novartis and Otsuka, The Silicon Review asks a final question. When a drug is the sixth to enter a rare disease market and must still prove it can slow kidney decline, does being first in its class matter more than being first to the finish line?

FAQ:

Q: What is Trutakna and what is it approved for?
A: Trutakna (atacicept-vymj) is a dual BAFF/APRIL inhibitor approved to reduce proteinuria in adults with primary IgA nephropathy at risk for disease progression. It is the first FDA-approved therapy to target both BAFF and APRIL.

Q: Who developed Trutakna?
A: Trutakna is developed by Vera Therapeutics, based in Brisbane, California. The company in-licensed the drug from Merck KGaA approximately six years ago.

Q: What data supported the FDA approval?
A: The approval was supported by a prespecified interim analysis of the ORIGIN 3 trial. Patients treated with Trutakna achieved a 46% reduction from baseline in proteinuria, a 42% reduction compared to placebo at 36 weeks.

Q: Is Trutakna a full approval or accelerated approval?
A: Trutakna received accelerated approval. Vera must confirm clinical benefit in a confirmatory trial showing the drug slows kidney function decline (eGFR data) before full approval can be granted.

Q: What competitors does Trutakna face?
A: Trutakna enters a crowded IgAN market with approved drugs including Novartis' Fabhalta (iptacopan), Otsuka's Voyxact (sibeprenlimab), Travere's Filspari (sparsentan), and Calliditas' Tarpeyo (budesonide).

Q: How is Trutakna administered?
A: Trutakna is administered via a once-weekly subcutaneous injection using an auto injector for self-administration at home. The dose is 150 mg.

Q: When will confirmatory data be available?
A: Vera expects eGFR data from the confirmatory ORIGIN 3 trial in the third quarter of 2026, with a supplemental BLA targeted for Q4 2026.